Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experience (Q36050378)

11 August 2017

Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experience (English)

1 reference

11 August 2017

Timothy B Niewold

3

0 references

author name string

Linda M Mileti

1

1 reference

11 August 2017

Mary E Strek

2

1 reference

11 August 2017

James J Curran

4

1 reference

11 August 2017

Nadera J Sweiss

5

1 reference

11 August 2017

1 August 2009

1 reference

Journal of Clinical Rheumatology

11 August 2017

1 reference

11 August 2017

15

1 reference

11 August 2017

5

1 reference

11 August 2017

254-255

1 reference

Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380442

Idiopathic inflammatory myopathies: A treatment update

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380442

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380442

Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380442

Lupus pneumonitis and anti-SSA(Ro) antibodies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380442

A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380442

Polymyositis and dermatomyositis (first of two parts)

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380442

Treatment of antisynthetase-associated interstitial lung disease with tacrolimus

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380442

The long-term outcome of anti-Jo-1-positive inflammatory myopathies

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380442

Interstitial lung disease in polymyositis and dermatomyositis

23 September 2018

1 reference

12 December 2020

Adult respiratory distress syndrome in polymyositis patients with the anti-Jo-1 antibody

1 reference

12 December 2020

Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis

1 reference

12 December 2020

Rituximab in the treatment of dermatomyositis: an open-label pilot study

1 reference

12 December 2020

In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease

1 reference

12 December 2020

10.1097/RHU.0B013E3181B0E910

Identifiers

DOI

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

19590436

1 reference